Prognostic role of Androgen Receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer.

ABSTRACT:

Background

The Androgen Receptor (AR) has emerged as an endocrine therapy target in Breast Cancer, exhibiting up to 80% expression in clinical cases. AR-V7, a constitutively activated splice variant of AR with a truncated ligand-binding domain (LBD), demonstrates ligand-independent transcriptional activity and resistance to nonsteroidal antiandrogens like Bicalutamide or Enzalutamide, targeting the LBD. In metastatic prostate cancer, elevated AR-V7 levels lead to therapeutic resistance and increased metastasis.

Methods

In this study, we evaluated the expression of AR and AR-V7 in cell lines and a cohort of 89 patients undergoing surgical intervention for treatment-naïve breast cancer. Further clinicopathological correlations and survival analysis were performed to evaluate t

SUBMITTER: Srivastava TP 

PROVIDER: S-EPMC11562864 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature